Dr. Melvin Andersen is Director, Program in Chemical Safety Sciences, The Hamner Institutes for Health Sciences, RTP, NC. During a 40-year career, he has over 400 papers and book chapter related to interpretation of toxicology studies for assessing safe exposure levels to chemicals.

He was recognized by ILSI (Institute for Scientific Information) as a 'highly cited' scientist. From 2004 to 2007, he served on the NAS Committee on Toxicity Testing of Environmental Agents that produced the report, "Toxicity Testing in the 21st Century: A Vision and A Strategy" and has given over 25 talks about the report and its implementation.

Eric Blomme received his D.V.M. from The University of Lyon (France), studied Management at McGill University, completed a residency in Veterinary Pathology at Cornell University and a Ph.D. at Ohio State University. His areas of expertise include preclinical safety assessment of new molecular entities using molecular toxicology and pathology. Eric joined Abbott Laboratories in 2003 where he has lead various projects in the area of predictive and mechanistic toxicology and discovery. In his prior positions at Monsanto/Searle and Pharmacia, Eric worked on various drug discovery and development projects. His publication record includes over 45 peer-reviewed manuscripts and book chapters.

Professor Emeritus of Toxicology and Environmental Health, University of Surrey, UK.

Professor Bridges has researched the toxic risks of chemicals to humans and the environment for over thirty years. He is the author or co-author of over 300 research papers and reviews in the fields of toxicology, drug metabolism, public health and methods of chemical analysis. His most recent research interests include risk assessment methodology and the health risks involved in waste management.

Professor Bridges started his career at St Mary's Hospital Medical School, London University. At the University of Surrey he initiated the postgraduate training programme in toxicology which was the first in Europe. He has held a variety of senior administrative posts at the University of Surrey, including Dean of Science.

Professor Bridges has, throughout his career, remained commited to developing international, multiprofessional collaboration in both research and education and to the effective interface of theory and practice. He has held visiting senior posts at South Western Medical School, Dallas, University of Rochester, New York, National Institute of Environmental Health Sciences, North Carolina and at CINVESTAV-IPN, Mexico City, Mexico. He has acted as external examiner for degrees in UK, Ireland, Sweden, Netherlands, France, Australia, New Zealand, Singapore and Hong Kong universities.

In addition to his university duties, Professor Bridges has been very active in a number of professional societies. He founded the British Toxicology Society, and was the first President of the Federation of the European Societies of Toxicology (now known as EUROTOX). He started the biannual series of European Drug Metabolism Workshops. He has also held office in the Biochemical Society (UK), the Society for Risk Analysis (European Chapter), the Institute of Biology (UK) and the European Society for Biochemical Pharmacology and the International Life Sciences Institute. He has served on many editorial boards and conference organising committees. For a number of years he was Chairman of the Scientific Committee for the Fund for Replacement of Animal in Medical Experiments (FRAME).

Professor Bridges has also served on many UK Government committees including: workplace standards (WATCH and Advisory Committee on Toxic Substances), Air Soil and Water Contaminants, Novel and Irradiated Foods, Veterinary Products, Major Incidents and the UK Veterinary Residues Committee.

Dr. Thomas A. Baillie currently is Dean of the School of Pharmacy at the University of Washington in Seattle, WA. He was born in Scotland and educated at the University of Glasgow, where he earned B.Sc. (Hons) and Ph.D. degrees in Chemistry in 1970 and 1973, respectively. He also holds an M.Sc. degree in Biochemistry from the University of London (1978) and was awarded the degree of D.Sc. in Chemistry from the University of Glasgow in 1992.

Following postdoctoral research at the Karolinska Institute in Stockholm, Sweden (1973-75), Dr. Baillie held successive faculty positions at the University of London (1975-78), University of California San Francisco (1978-81), and University of Washington (1981-94). He then joined Merck Research Laboratories in West Point, PA, where he was Global Vice President of Drug Metabolism & Pharmacokinetics until 2008, when he returned to the University of Washington to assume his present responsibilities.

Dr. Baillie's research interests center on the application of mass spectrometry and allied techniques to mechanistic studies on the metabolism of foreign compounds, with particular emphasis on the generation of chemically-reactive, potentially toxic products of biotransformation. He has co-authored some 200 peer-reviewed publications, serves on the Advisory Boards of a number of journals and academic research centers, and acts as a consultant to several companies in the pharmaceutical and biotechnology industries. He was awarded a Fogarty Senior International Fellowship from the NIH in 1988, was the recipient of the James R. Gillette Award from the American Society for Pharmacology & Experimental Therapeutics (2001), and received the Lifetime Achievement Award from the International Isotope Society (2009).

Sabcho Dimitrov is Associate Professor of Department of Computer and Information Technologies and Deputy Head of the Laboratory of Mathematical Chemistry at Bourgas Prof. Assen Zlatarov University. He obtained a M. Sc. in Technology of the plastics, M. Sc. in Theoretical methods for investigation of polymers from Bourgas University and PhD in Chemical engineering from Bulgarian Academy of Science.

Dr. Dimitrov is experienced in parameter estimation, data analysis and mathematical modeling. He is involved in the development of models for predicting environmental fate and (eco)toxicity of chemicals accounting for their metabolism.

Thomas Hartung is director of the Center for Alternatives to Animal Testing (CAAT) and the Doerenkamp-Zbinden Professor and Chair for Evidence-based Toxicology in the Department of Environmental Health Sciences at the Johns Hopkins Bloomberg School of Public Health.

His career began on the faculty at the University of Konstanz, Germany, where he served as an assistant professor of biochemical pharmacology and an associate, and later full professor of pharmacology and toxicology. He also served as the CEO of the Steinbeis Technology Transfer Center for In Vitro Pharmacology and Toxicology.

Prior to his position at CAAT, Dr. Hartung was the head of the European Centre for Alternative Methods (ECVAM) at the European Commission Joint Research Centre in Italy. As head of ECVAM, he was integral in accelerating the alternative methods validation process and in enabling a network of more than 400 experts from all stakeholder groups to facilitate global regulatory harmonization in toxicity testing.

Dr. Hartung received a PhD in biochemical pharmacology from the University of Konstanz and an MD in toxicology from the University of Tubingen, Germany.

Elaine Holmes a Professor of Chemical Biology at Imperial College London and Head of Biomolecular Medicine. She obtained a BSc in Biology and PhD in Chemistry from London University and has a background in spectroscopic techniques and chemometric analysis. Her work centres on the development of expert systems for the prediction of drug toxicity and disease. To date she has published over 150 peer reviewed articles and has edited and co-authored several books in metabonomics and related subjects.

She has successfully graduated 11 PhD students in Chemistry the last 9 years (since holding an academic position at Imperial). She is a Visiting Professor of Wuhan Institute of Physics and Mathematics, Chinese Acadamy of Sciences and the 2007 William Glasser Visiting Professor of University of the Sciences, Philadelphia. Ehe is a member of several editorial boards including Chemical Research in Toxicology, Journal of Proteome Sciences and Toxicological Sciences.

Her major application areas for spectroscopic and chemometric research lie in the fields of cardiovascular disease, gasterointestinal disorders, parasitology, neurodegeneration and toxicology. Holmes is also a founder director of an Imperial spin out company Metabometrix.

Tom Holmes is a Regulatory Toxicologist representing Agchem Project Consulting Ltd (APC), a regulatory consultancy that provides regulatory and technical support for plant production products, biocides and general chemicals.

Tom began training as a toxicologist in 1996 at the UK Government pesticide regulatory agency, the Pesticides Safety Directorate (PSD, now the Chemicals Regulation Directorate). Whilst at PSD, Tom completed a part time MSc at Sheffield Hallam University in the Biomedical Basis of Disease, and became a UK and Eurotox registered toxicologist. The results from his MSc thesis were published.

His duties at CRD included evaluation of toxicology data submitted in support of applications for pesticide approvals, preparing summaries for independent expert advisory committees and other forums, and providing toxicological guidance to colleagues and applicants. Peer review of toxicological evaluations produced at PSD and counterparts in other Member States were an important duty, and development of position papers using PSD's extensive toxicological database.

In 2006, Tom took the role of Regulatory Affairs Manager with Covance Laboratories, delivering expert toxicology consultancy and regulatory services to pharmaceutical, industrial chemical, and agrochemical clients. He provided advice on toxicology programs, unusual findings in toxicology studies and wrote cases and opinions for consideration by regulators. Tom's advice and input has accelerated clients' drugs into the clinic, successfully defended existing products, and prevented product recalls.

In 2010 Tom moved to APC and continues to provide expert toxicology and registration services to clients in all fields.

Hiroyuki Kusuhara, Ph.D. is currently Associate Professor of Department of Molecular Pharmacokinetics at Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.

He has graduated from the Graduate School of Pharmaceutical Sciences, The University of Tokyo, in 1996 (M.S.). He started his carrier as an academic scientist in The University of Tokyo as Assistant Professor of Pharmaceutical Sciences (1998). He was promoted to Associate Professor of Graduate School of Pharmaceutical Sciences, The University of Tokyo (2004). He received his Ph.D. from The University of Tokyo supervised by Prof. Yuichi Sugiyama in 2003.

His major research interest is the role of drug transporters in the drug disposition.

William B. Mattes, PhD, DABT, is the founder and principal of PharmPoint Consulting, providing expertise in cutting edge drug development, biomarker implementation, mechanistic, genetic, molecular and genomic toxicolog, and collaboration leadership.

Dr. Mattes' background is in drug development, genetic toxicology, molecular toxicology, mechanistic toxicology, and toxicogenomics, spanning more than 25 years. Prior to establishing PharmPoint Consulting, Dr. Mattes was Director of Toxicology at the Critical Path Institute where he developed and directed the Predictive Safety Testing Consortium (PSTC), a collaboration of 16 of the world's major pharmaceutical companies, with FDA and EMEA advisors, with the goal of qualifying new biomarkers for drug safety in a regulatory setting. Dr. Mattes was also senior scientific director of Toxicogenomics at Gene Logic, associate director of toxicogenomics at Pharmacia Corp, Kalamazoo, MI, group leader of experimental toxicology at Ciba Pharmaceuticals, Summit, NJ, and group leader of molecular and cellular toxicology, Ciba-Geigy Agricultural Chemical Division, Farmington, CT.

Dr. Mattes received his BA from the University of Pennsylvania and PhD in biological chemistry from the University of Michigan, Ann Arbor. He did his postdoctoral training in biochemistry at the Johns Hopkins University, and was a staff fellow at the National Cancer Institute, the National Institutes of Health (NCI/NIH). In 1997 Dr. Mattes became a diplomate of the American Board of Toxicology. He is a full member of the Society of Toxicology (SOT). As part of his involvement with the International Life Sciences Institutes (ILSI) Health and Environmental Sciences (HESI) Committee on the application of genomics to risk assessment, Dr. Mattes chaired the subcommittee that established a public toxicogenomics database at the European Bioinformatics Institute. His research interests include bioinformatics, cross-species comparisons of molecular responses, mitochondrial toxicity and dose/time/response relationships in gene expression. He also currently fills the guitar chair for the group Jazzicology at the American College of Toxicology annual meeting.

Dr Dennis Smith worked in the pharmaceutical industry for 32 years after gaining his Ph.D from the University of Manchester. For 20 years he was at Pfizer Global Research and Development, Sandwich where he was Vice President-Pharmacokinetics, Dynamics and Metabolism.

During this 30-year span he has helped in the Discovery and Development of eight marketed NCEs. He has authored over 100 publications including two books.

For the past 2 years he has been a Pfizer Academic Research Fellow working on a part-time basis. His research interests and publications span all aspects of Drug Discovery and Development particularly where drug metabolism knowledge can impact on the design of more efficacious and safer drugs.

He is active in a teaching role holding appointments as Visiting Professor at the University of Liverpool and Honorary Senior Lecturer at the University of Aberdeen and lectures widely to students at several other Universities.

Alexander Tropsha is K.H. Lee Distinguished Professor and Chair of the Division of Medicinal Chemistry and Natural Products in the Eshelman School of Pharmacy, UNC-Chapel Hill. He received PhD in Chemical Enzymology in 1986 from Moscow State University, Russia.

His research interests are in the areas of computational drug discovery, toxicology, cheminformatics, and structural bioinformatics. His has authored 130+ research papers and co-edited two monographs. He is a member of several editorial boards, permanent member of the BDMA Study Section at the NIH and an elected member of the Board and vice-chair of the international Cheminformatics and QSAR Society.

Dr. Trosko is the Director of the Division of Genetic & Epigenetic Toxicology, Human Adult Stem Cell Biology and Oncology, Dept. of Pediatrics/Human Development, College of Human Medicine at Michigan State University. Starting his research career in DNA Damage/repair/mutagenesis at Oak Ridge National Laboratory, he has published over 400 publications and book chapters and gave over 700 invited lectures related to genetic toxicology, cancer research, epigenetic toxicology, human adult stem cells, role of diet on modifying chronic diseases and "bioethics" during his 44 years since joining Michigan State University

Dr. Trosko , mentored by Drs. Sheldon Wolf,. Ernest Chu, R.B. Setlow, and Van R.Potter, worked on cancer-prone syndromes ( xeroderma pigmentosum, Blooms, Cockynes, Downs), helped to develop DNA repair and in vitro mammalian mutation assays, development the gap junction intercellular communication assay to detect both epigenetic toxicants and chemopreventive assays, isolated human adult stem cells, and pioneered the area of "epigenetic toxicology". He spent research leaves of absence at the McArdle Laboratory of Cancer Research-U. Wisconsin; Radiation Effects Research Foundation-Hiroshima & Nagasaki, Japan as Chief of Research; Seoul National University, Korea as "Invited Korean Ministry of Science's "Brain Pool" awardee; Invited Distinguished Professor of Oncology at ARNAS-Civico, Palermo, Sicily; National Institute of Health Sciences-Tokyo as a Japan Society for Promotion of Science Awardee; and recently, at Seoul National University as a "World Class University" Distinguished Invited Professor". He receive the first, "Scientific Achievement" Award from the Society of Toxicology.

Antony Williams is the Vice President of Strategic Development at the Royal Society of Chemistry and is the host of ChemSpider, a free online structure centric community for chemists. ChemSpider began as a hobby project in a basement and went on to become one of the most popular Chemistry websites with the highest quality of data available online.

Antony spent over a decade in the commercial scientific software business as Chief Science Officer for ACD/Labs. He is an accomplished NMR spectroscopist with over 100 peer-reviewed publications. During his career he was the NMR Technology Leader for the Eastman-Kodak company and has worked in both academia and national government research institutions.

Robert Glen obtained his Ph.D. in X-ray Crystallography and Organic Synthesis from the University of Stirling. One of the highlights was the first co-crystallisation of a reactant and product of a chemical reaction in a single crystal. At the Wellcome Foundation he set up the Computer-aided Molecular Design group. This included Protein Crystallography, Molecular Transport properties and Electrochemistry. He co-developed the GASP and GOLD computer programs which are used extensively in the pharmaceutical industry, is a co-inventor of Zomig for migraine and invented two other compounds that have entered Phase-2 development.

He then became Vice President for Collaborative Research at Tripos Inc., a biotechnology company. He assisted in setting up three biotechnology companies and directed collaborative research and contract research in drug discovery.

In 1999 he moved to the University of Cambridge as Director of the new Unilever Centre, a £11.5 million addition to the Chemistry department, which has expanded to over forty people. He has published over 100 papers and has numerous patents.

Following a PhD in organic chemistry David Hawkins began his career as a synthetic chemist in drug research for a major pharmaceutical company. Subsequently he has spent more than 30 years working in the area of metabolism and pharmacokinetics, and has been responsible for directing the work of scientists as head of a scientific division in a contract research organisation.

He has published more than 100 scientific papers and reviews covering a range of different aspects of xenobiotic metabolism and was the founding editor of the book series 'Biotransformations' published by the Royal Society of Chemistry.

More recently he became involved in development of methodologies for the in silico prediction of metabolism and toxicity based on structure-activity relationships. He now serves as a scientific advisor to Lhasa Limited, and is currently a member of the charity's Board of Directors.

Alan G. E. Wilson, PhD, ATS, is currently Vice President of Drug Metabolism, Pharmacokinetics, and Toxicology and Pathology at Lexicon Pharmaceuticals. He is internationally recognized in drug metabolism, pharmacokinetics and toxicology and has over 25 years of experience working on product discovery and development for both small molecules and biotherapeutics.

He has significant hands-on experience with the regulatory and GLP requirements for the conduct of ADME, PK, CMC and safety assessment studies to support regulatory submissions and clinical studies. Prior to joining Lexicon, Dr. Wilson held senior management and leadership positions with major international pharmaceutical and life science companies including Searle, Pharmacia and Pfizer.

He is internationally recognized in drug metabolism, pharmacokinetics and toxicology and has more than 25 years of experience working on product discovery and development. He has been involved with the registration of several successful marketed products and has extensive experience working with regulatory agencies in the United States, Europe and Asia Pacific.

Dr. Wilson has Board of Director and Scientific Advisory experience with several companies. He is Board Certified in Toxicology and has produced more than 120 publications. He received his Ph.D. in Drug Metabolism/PK from the University of Surrey, U.K. and his B.S. in biochemistry from the University of Surrey, U.K. Dr. Wilson has been an invited speaker and presenter at many international conferences.